Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone

Skin
08 May 2019
https://jofskin.org/index.php/skin/article/view/722

Erythromelalgia is a rare condition that may be associated with a variety of underlying conditions and is often refractory to therapy. We report a case of a patient with mast cell activation syndrome who developed erythromelalgia and responded to low dose naltrexone.

Leonard Weinstock, MD - POTS and Mast Cell Activation Syndromes (2017 Conference) (LDN, low dose naltrexone)

Dr Leonard Weinstock is from St Louis in Missouri and helps patients with GI Issues and other autoimmune conditions.

Gastroenterologist Dr Leonard Weinstock - 11th March 2020 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: Today, I'd like to welcome my guest, Dr Leonard Weinstock. He's a gastroenterologist from Missouri. Thank you for joining us today. 

Dr Leonard Weinstock: You’re welcome. 

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.